Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Accumulated Expenses (2016 - 2025)

BioCorRx (BICX) has disclosed Accumulated Expenses for 9 consecutive years, with $359378.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed N/A to $359378.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $359378.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $359378.0 for FY2025, N/A changed from the prior year.
  • Accumulated Expenses hit $359378.0 in Q4 2025 for BioCorRx, up from $317577.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $359378.0 in Q4 2025 to a low of $299.0 in Q2 2021.
  • Historically, Accumulated Expenses has averaged $118436.0 across 3 years, with a median of $1652.0 in 2022.
  • Biggest YoY gain for Accumulated Expenses was 730.56% in 2021; the steepest drop was 449.16% in 2021.
  • Year by year, Accumulated Expenses stood at $983.0 in 2021, then soared by 68.06% to $1652.0 in 2022, then skyrocketed by 21654.12% to $359378.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BICX at $359378.0 in Q4 2025, $317577.0 in Q3 2025, and $147871.0 in Q2 2025.